NewAmsterdam制药公司公布了2024财年全年财务业绩。 现金状况：截至2024年12月31日，新阿姆斯特丹的现金及现金等价物为7.717亿美元，另有6250万美元的有价证券，而2023年12月31日的现金及现金等价物为3.405亿美元。现金增加主要来自于年度内完成的后续公开发行股票所得收益、临床开发里程碑的达成、认股权证和期权行使部分抵消了公司在药物开发和支持公司发展的销售、管理等费用上的支出。 收入：截至2024年12月31日，NewAmsterdam全年收入为4560万美元，而2023年同期为1410万美元。收入增加主要由于达成临床成功里程碑以及获得一般开发成本补偿。 研发费用：2024年研发费用为1.514亿美元，而2023年为1.594亿美元。研发费用减少主要由于临床试验制造和临床费用降低，部分被人员和监管费用的增加所抵消。 销售、管理费用：2024年销售、管理费用为7040万美元，而2023年为3760万美元。费用增加主要由于增加人员及市场营销和宣传费用，以支持计划中的新药Obicetrapib商业化。 净亏损：2024年净亏损为2.416亿美元，而2023年净亏损为1.769亿美元。变化的原因包括上文描述的各部分以及衍生负债公允价值变动的非现金损失。

以上内容来自Benzinga Earnings专栏，原文如下：

Full Year 2024 Financial Results

• Cash Position: As of December 31, 2024, NewAmsterdam recorded cash and cash equivalents of $771.7 million and $62.5 million of marketable securities, compared to $340.5 million as of December 31, 2023. The increase in cash is primarily driven by the proceeds of the follow-on public equity offerings completed during the year, the achievement of a clinical development milestone, warrant exercises and option exercises, partially offset by cash outflows related to research and development costs as the Company continues development of obicetrapib and increased spending on selling, general and administrative expenses to support the Company's growing organization.
• Revenue: NewAmsterdam recognized $45.6 million in revenue for the year ended December 31, 2024, compared to $14.1 million in the year ended December 31, 2023. This increase is primarily due to an increase in the revenue recognized related to the achievement of a clinical success milestone and the recognition of revenue related to a general development cost reimbursement.
• Research and Development ("R&D") Expenses: R&D expenses were of $151.4 million for year ended December 31, 2024, compared to $159.4 million in the year ended December 31, 2023. This decrease is primarily due to a decrease in manufacturing and clinical costs due to clinical trials which are complete or nearing completion, partially offset by an increase in personnel and regulatory expenses.
• Selling, General and Administrative ("SG&A") Expenses: SG&A expenses were $70.4 million for the year ended December 31, 2024, compared to $37.6 million in the year ended December 31, 2023. This increase is primarily due to increased personnel and marketing and communication costs as we begin to expand and build capabilities to support our planned commercial launch of obicetrapib, if approved.
• Net loss: Net loss for the year ended December 31, 2024 was $241.6 million, compared to net loss of $176.9 million in the year ended December 31, 2023. The individual components of the change are described above in addition to non-cash losses related to changes in the fair value of our derivative liabilities.